129 related articles for article (PubMed ID: 16326409)
21. Rituximab added to an intensified salvage chemotherapy program followed by autologous stem cell transplantation improved the outcome in relapsed and refractory aggressive non-Hodgkin lymphoma.
Sieniawski M; Staak O; Glossmann JP; Reineke T; Scheuss H; Diehl V; Engert A; Josting A
Ann Hematol; 2007 Feb; 86(2):107-15. PubMed ID: 17103169
[TBL] [Abstract][Full Text] [Related]
22. Treatment of pediatric non-Hodgkin lymphoma in Hungary: 15 years experience with NHL-BFM 90 and 95 protocols.
Müller J; Csóka M; Jakab Z; Ponyi A; Erlaky H; Kovács G
Pediatr Blood Cancer; 2008 Mar; 50(3):633-5. PubMed ID: 17366531
[TBL] [Abstract][Full Text] [Related]
23. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.
Andersen NS; Pedersen LB; Laurell A; Elonen E; Kolstad A; Boesen AM; Pedersen LM; Lauritzsen GF; Ekanger R; Nilsson-Ehle H; Nordström M; Fredén S; Jerkeman M; Eriksson M; Väärt J; Malmer B; Geisler CH
J Clin Oncol; 2009 Sep; 27(26):4365-70. PubMed ID: 19652064
[TBL] [Abstract][Full Text] [Related]
24. Haematopoietic stem cell transplantation as primary therapy of sporadic adult Burkitt lymphoma.
Song KW; Barnett MJ; Gascoyne RD; Horsman DE; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Nevill TJ; Shepherd JD; Smith CA; Sutherland HJ; Voss NJ; Toze CL; Connors JM
Br J Haematol; 2006 Jun; 133(6):634-7. PubMed ID: 16704438
[TBL] [Abstract][Full Text] [Related]
25. Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma.
Ladetto M; Magni M; Pagliano G; De Marco F; Drandi D; Ricca I; Astolfi M; Matteucci P; Guidetti A; Mantoan B; Bodoni CL; Zanni M; Boccadoro M; Gianni AM; Tarella C
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1270-6. PubMed ID: 17162208
[TBL] [Abstract][Full Text] [Related]
26. Successful treatment with modified CHOP-rituximab in pediatric AIDS-related advanced stage Burkitt lymphoma.
Crosswell HE; Bergsagel DJ; Yost R; Lew G
Pediatr Blood Cancer; 2008 Apr; 50(4):883-5. PubMed ID: 17278123
[TBL] [Abstract][Full Text] [Related]
27. Post cardiac transplantation lymphoproliferative disorder presenting as t(8;14) Burkitt leukaemia/lymphoma treated with low intensity chemotherapy and rituximab.
Windebank K; Walwyn T; Kirk R; Parry G; Hasan A; Bown N; Wilkins B
Pediatr Blood Cancer; 2009 Sep; 53(3):392-6. PubMed ID: 19459198
[TBL] [Abstract][Full Text] [Related]
28. [Autologous hematopoietic stem cell transplantation for aggressive B-cell non-Hodgkin's lymphoma].
Hirose A; Yamane T; Nakajima Y; Manabe M; Kanashima H; Hagihara K; Sakamoto E; Nakamae M; Terada Y; Kosaka S; Aoyama Y; Sakamoto C; Kumura T; Koh KR; Hirai M; Ohta K; Nakao Y; Mugitani A; Teshima H; Hino M
Gan To Kagaku Ryoho; 2005 Dec; 32(13):2059-64. PubMed ID: 16352929
[TBL] [Abstract][Full Text] [Related]
29. Anti-CD20 monoclonal antibody (Rituximab) for therapy of mediastinal CD20-positive large B-cell non-Hodgkin lymphoma with a local tumor extension into the lung of a 10-year-old girl.
Culić S; Culić V; Armanda V; Kuljis D; Pesutić-Pisac V; Janković S
Pediatr Hematol Oncol; 2003 Jun; 20(4):339-44. PubMed ID: 12746167
[TBL] [Abstract][Full Text] [Related]
30. Practice guidelines for the management of extranodal non-Hodgkin's lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.
Zinzani PL; Martelli M; Poletti V; Vitolo U; Gobbi PG; Chisesi T; Barosi G; Ferreri AJ; Marchetti M; Pimpinelli N; Tura S; ; ;
Haematologica; 2008 Sep; 93(9):1364-71. PubMed ID: 18603558
[TBL] [Abstract][Full Text] [Related]
31. A Burkitt's lymphoma case with eyelid, renal and pulmonary involvement.
Köksal Y; Reisli I; Uçar C; Avunduk M; Açikgözoğlu S; Calişkan U
Turk J Pediatr; 2006; 48(2):181-4. PubMed ID: 16848125
[TBL] [Abstract][Full Text] [Related]
32. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study.
Sebban C; Brice P; Delarue R; Haioun C; Souleau B; Mounier N; Brousse N; Feugier P; Tilly H; Solal-Céligny P; Coiffier B
J Clin Oncol; 2008 Jul; 26(21):3614-20. PubMed ID: 18559872
[TBL] [Abstract][Full Text] [Related]
33. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
34. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
Collins-Burow B; Santos ES
Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
[TBL] [Abstract][Full Text] [Related]
35. Do cytogenetic abnormalities precede morphologic abnormalities in a developing malignant condition?
Northup JK; Gadre SA; Ge Y; Lockhart LH; Velagaleti GV
Eur J Haematol; 2007 Feb; 78(2):152-6. PubMed ID: 17313561
[TBL] [Abstract][Full Text] [Related]
36. Is high-dose chemotherapy after primary chemotherapy a therapeutic option for patients with primary mediastinal nonseminomatous germ cell tumor?
Banna GL; De Giorgi U; Ferrari B; Castagna L; Alloisio M; Marangolo M; Rosti G; Santoro A
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1085-91. PubMed ID: 17084372
[TBL] [Abstract][Full Text] [Related]
37. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study.
Martín A; Conde E; Arnan M; Canales MA; Deben G; Sancho JM; Andreu R; Salar A; García-Sanchez P; Vázquez L; Nistal S; Requena MJ; Donato EM; González JA; León A; Ruiz C; Grande C; González-Barca E; Caballero MD;
Haematologica; 2008 Dec; 93(12):1829-36. PubMed ID: 18945747
[TBL] [Abstract][Full Text] [Related]
38. [Very late recurrence (14 years) of a lymphoblastic leukemia-lymphoma].
Delgado JR; Carrión JR; Pérez-Manga G; Mayayo M; Ramos M
Med Clin (Barc); 1989 Jul; 93(5):178-80. PubMed ID: 2796447
[TBL] [Abstract][Full Text] [Related]
39. Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma.
Leonard JP; Gregory SA; Maloney DG; Vose JM; Younes A; Zelenetz AD
Clin Adv Hematol Oncol; 2008 Jun; 6(6):437-45. PubMed ID: 18567989
[TBL] [Abstract][Full Text] [Related]
40. Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents--a Berlin-Frankfurt-Münster group report.
Woessmann W; Peters C; Lenhard M; Burkhardt B; Sykora KW; Dilloo D; Kremens B; Lang P; Führer M; Kühne T; Parwaresch R; Ebell W; Reiter A
Br J Haematol; 2006 Apr; 133(2):176-82. PubMed ID: 16611309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
